Interestingly, it was recently shown that dementia and Parkinson’s disease patients without BP may also develop cerebrospinal fluid (CSF) anti-BP180 antibodies to non-pathogenic intracellular and extracellular domains and, rarely, to pathogenic NC16A domain of BP180 [13]. Here, COL17A1 is linked to Parkinson disease.